PMID- 23586000
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130416
LR  - 20211021
IS  - 2155-7772 (Print)
IS  - 2155-7780 (Electronic)
IS  - 2155-7780 (Linking)
VI  - 14
IP  - 6
DP  - 2012
TI  - Importance of gender in the treatment of schizophrenia.
LID - 10.4088/PCC.12m01407 [doi]
LID - PCC.12m01407
AB  - OBJECTIVE: To compare male and female patients participating in e-STAR 
      (electronic Schizophrenia Treatment Adherence Registry), an international, 
      prospective, observational study assessing use of risperidone long-acting 
      injection in patients with schizophrenia or schizoaffective disorder in both the 
      Czech and Slovak Republics. METHOD: The demographic, clinical, and 
      treatment-related data were collected at baseline and then prospectively for 24 
      months. We focused on gender differences in demographic and clinical data 
      (hospitalizations, concomitant medication, and clinical improvement using 
      Clinical Global Impressions-severity of illness [CGI-S], Global Assessment of 
      Functioning [GAF], and Personal and Social Performance [PSP] scales). All 
      psychiatric diagnoses were made according to International Classification of 
      Diseases, Tenth Revision criteria. Data were collected from September 2006 
      through September 2009. RESULTS: A total of 868 patients (488 men and 380 women) 
      were included in the assessment. At baseline, the women were significantly older 
      than the men (42.1 +/- 12.8 vs 34.8 +/- 11.1 years, respectively; P < .0001). The 
      women were also significantly more frequently diagnosed with schizoaffective 
      disorder (P = .0048). There was no difference between men and women in the 
      proportion of patients hospitalized in the retrospective and prospective period 
      (including length of stay). At 24 months, the men were taking fewer 
      antidepressants and benzodiazepines than the women (controlled for baseline 
      values). In men and women, a significant decrease in the CGI-S score (P < .001) 
      and a significant increase in the GAF and PSP scores (P < .001) from baseline 
      were observed. The improvements in CGI-S and PSP scores were similar in both 
      groups (no significant difference between male and female patients). The 
      improvement (increase) in the mean GAF score was significantly higher in women 
      than in men (P = .0317). CONCLUSIONS: The treatment with risperidone long-acting 
      injection was associated with clinically significant improvement in both male and 
      female patients with schizophrenia with comparable severity of illness. There 
      were no significant differences in most outcome measures. Gender differences, 
      especially concerning treatment response to individual antipsychotics and their 
      different forms, should be more intensively studied.
FAU - Ceskova, Eva
AU  - Ceskova E
AD  - Central European Institute of Technology, Masaryk University, and Masaryk 
      University and Faculty Hospital, Brno, Czech Republic.
FAU - Prikryl, Radovan
AU  - Prikryl R
LA  - eng
PT  - Journal Article
DEP - 20121115
PL  - United States
TA  - Prim Care Companion CNS Disord
JT  - The primary care companion for CNS disorders
JID - 101547532
PMC - PMC3622539
EDAT- 2012/01/01 00:00
MHDA- 2012/01/01 00:01
PMCR- 2012/01/01
CRDT- 2013/04/16 06:00
PHST- 2012/05/03 00:00 [received]
PHST- 2012/08/13 00:00 [accepted]
PHST- 2013/04/16 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2012/01/01 00:01 [medline]
PHST- 2012/01/01 00:00 [pmc-release]
AID - 12m01407 [pii]
AID - 10.4088/PCC.12m01407 [doi]
PST - ppublish
SO  - Prim Care Companion CNS Disord. 2012;14(6):PCC.12m01407. doi: 
      10.4088/PCC.12m01407. Epub 2012 Nov 15.